End Stage Renal Disease, Kidney Disease, Protein Energy Wasting
Conditions
Keywords
End Stage Renal Disease, ESRD, Maintenance Hemodialysis, Hemodialysis, Dialysis, MHD, Protein Energy Wasting, PEW
Brief summary
This is a pilot study to assess the safety, pharmacokinetics and effectiveness of PINTA 745 or placebo in treating protein energy wasting (PEW) in patients receiving maintenance hemodialysis (MHD).
Detailed description
This is a randomized (participants will be assigned by chance to study treatments), double-blind (participants and study personnel will not know the identity of the study treatments), placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial)-controlled study in patients who receive maintenance hemodialysis. Three participants will receive PINTA 745 for every participant that receives placebo. PINTA 745 or placebo will be taken intravenously once per week following dialysis. The study period will consist of screening, treatment for 12 weeks, and follow up for 8 weeks. Evaluations will be performed to assess the safety, pharmacokinetics (study of what the body does to a drug), pharmacodynamics (study of what a drug does to the body) and effectiveness in treating protein energy wasting (such as increasing muscle size and muscle function) throughout the study.
Interventions
DRUGPINTA 745
PINTA 745 will be administered once weekly by IV infusion. Cohort dose schedules: * 3mg/kg weekly for 12 weeks * 3mg/kg for 3 weeks, followed by 1mg/kg for 9 weeks * 6mg/kg for 3 weeks, followed by 2mg/kg for 9 weeks
DRUGPlacebo
Placebo will be administered once weekly by IV infusion. Cohort dose schedules: * 3mg/kg weekly for 12 weeks * 3mg/kg for 3 weeks, followed by 1mg/kg for 9 weeks * 6mg/kg for 3 weeks, followed by 2mg/kg for 9 weeks
Sponsors
Pinta Biotherapeutics
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* ESRD patient and on outpatient maintenance hemodialysis for ≥ 6 months * Adequate dialysis with Kt/V ≥ 1.2 on two occasions within 12 weeks of enrollment * Undergoing dialysis at least 3 times per week, on average * Serum albumin ≤ 3.8g/dL within 60 days of enrollment * Able and willing to provide Informed consent
Exclusion criteria
* Presence of an indwelling central vascular catheter * Current medical condition that would interfere with ability to perform physical function tests * Active infection requiring hospitalization or antibiotics within the past month * Major surgery within past 3 months, minor surgery within the past 4 months * Dialysis access revision/angioplasty/replacement within the past 2 weeks * History of renal transplant, whether or not functional, within 2 years (however, if graft has been removed, patient will be considered eligible) or plans to undergo renal transplantation within 6 months * History of neoplasia, except non-melanoma skin cancers, with a 30% probability of recurrence within 12 months * Current treatment with appetite stimulants, anabolic steroids or growth hormone * Clinically significant heart disease * Difficulty swallowing food or liquid * If female, currently breast feeding * If female, pregnant * If female or male, unwilling to use a highly effective method of contraception
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum Tolerated Dose and Percent Changes in Lean Body Mass (LBM) | MTD will be assessed after the last patient in Cohort 1A and Cohort 2A complete 28 days on treatment. LBM will be assessed for comparing baseline to Week 12 | To evaluate the safety, dose-limiting toxicities (DLTs), maximum tolerated dose (MTD) and pharmacokinetics of PINTA 745 and to evaluate percentage change in LBM relative to baseline at 12 weeks, via dual-energy x-ray absorptiometry(DXA) scans, in the group receiving PINTA 745 at the MTD (or if no MTD is reached, at the recommended phase 2 dose) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Muscle Composition - Lean Body Mass (LBM), Appendicular Lean Mass (ALM) and Mid Upper Arm Muscle Circumference (MUAMC) | Baseline through Week 20 | To evaluate the change in LBM and ALM via CT and dual-energy x-ray absorptiometry (DXA) scans relative to baseline at 12, 16 and 20 weeks. To evaluate change relative to baseline in MUAMC at 5, 9, 16 and 20 weeks. |
| Change in Physical Function | Baseline through Week 20 | To evaluate change in physical function as measured by the Stair Climbing Power Test (SCPT) and the 6 Minute Walk Test (6MWT) relative to baseline at 5, 9, 12, 16 and 20 weeks |
Countries
United States
Outcome results
None listed